文献速递肿瘤 PET/CT

18F-DCFPyL PET/CT 用于 160 例高危前列腺癌患者初诊分期:转移检出率、对临床管理的影响及疗效初步结果

18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-27

研究纳入 2018 年 2 月至 2019 年 4 月 160 例高危前列腺癌患者,以 18F-DCFPyL PET/CT 作为初诊分期一线影像。90 例(56%)发现转移,仅 2/160 例(1%)因结果不明确需额外诊断影像,17% 患者的管理因此改变。作者认为该检查可作为高危前列腺癌初诊分期的一线影像用于治疗选择,多数患者无需进一步诊断影像。

要点

  • 160 例高危前列腺癌患者中 90 例(56%)经 18F-DCFPyL PET/CT 发现转移。
  • 仅 2/160 例(1%)因 PET/CT 结果不明确而需要额外诊断影像。
  • 18F-DCFPyL PET 改变了 17% 患者的管理。

核心结论

  • 18F-DCFPyL PET/CT 可作为高危前列腺癌初诊分期的一线影像用于治疗选择,多数患者无需进一步诊断影像。

研究设计与样本

  • 2018 年 2 月至 2019 年 4 月,所有高危前列腺癌患者接受 18F-DCFPyL PET/CT 进行分期。
  • 收集并评估基线特征、PET/CT 所见、所需额外诊断操作的数量与类型、额外诊断操作所见,以及接受根治性治疗患者的治疗对 PSA 水平的影响。
  • 共纳入 160 例患者。

主要发现

  • 160 例中 90 例(56%)有转移证据,N1、M1a、M1b、M1c 分别为 49%、28%、31%、3%。
  • 2/160 例(1%)因 18F-DCFPyL PET/CT 结果不明确需要额外诊断影像。
  • 81 例有 PSMA 阳性淋巴结转移,其中 39 例(48%)在 CT 上无肿大淋巴结。
  • 在 CT 显示淋巴结转移的 42 例中,18F-DCFPyL PET 在 41 例中检出额外转移淋巴结。
  • 18F-DCFPyL PET 改变了 17% 患者的管理。

临床怎么用

  • 作者认为 18F-DCFPyL PET/CT 可作为高危前列腺癌初诊分期的一线影像用于治疗选择,多数患者无需进一步诊断影像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT shows better diagnostic performance for detection of lymph node and bone metastases as compared to conventional imaging. Studies of PSMA PET/CT in primary staging comprise highly selected patient cohorts. This study evaluates 18F-DCFPyL PET/CT as first-line imaging modality for primary staging of high-risk prostate cancer. MATERIAL: From February 2018 until April 2019, all patients with high-risk prostate cancer received 18F-DCFPyL PET/CT for staging of prostate cancer. Baseline characteristics, findings at 18F-DCFPyL PET/CT, number and type of required additional diagnostic procedures, findings at additional diagnostic procedures, and effects of therapy on PSA levels for all patients treated with curative intent were collected and evaluated. RESULTS: One hundred-sixty patients were included in the study of which 90 (56%) had evidence of metastasized disease (N1, M1a, M1b and, M1c in 49%, 28%, 31%, and 3% respectively). Additional diagnostic imaging was needed in 2/160 patients (1%) because of equivocal findings on 18F-DCFPyL PET/CT. Eighty-one patients had evidence of PSMA-positive lymph node metastases, of whom 39 (48%) had no enlarged lymph nodes on CT; 18F-DCFPyL PET detected additional metastatic lymph nodes in 41/42 patients that had evidence of lymph node metastases on CT. 18F-DCFPyL PET altered patients' management in 17% of patients. CONCLUSION: 18F-DCFPyL PET/CT can be used as first-line imaging modality for therapy selection in patients with primary high-risk prostate cancer, without need for further diagnostic imaging procedures in the majority of patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wondergem M, van der Zant FM, Broos WAM, et al. 18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32719916. doi:10.1007/s00259-020-04782-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。